Securities code: Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) securities abbreviation: Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) Announcement No.: 2022029 Luoxin Pharmaceuticals Group Stock Co.Ltd(002793)
Announcement on winning the bid for participating in the centralized procurement of drugs by the alliance of Jiangxi, Guangdong, Henan and Hubei Provinces
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Recently, Jiangxi pharmaceutical procurement service platform released the notice on publishing the successful results of drug procurement by the alliance of Jiangxi, Guangdong, Henan and Hubei provinces. Shandong Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) (hereinafter referred to as “the company”), a subsidiary of Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) (hereinafter referred to as “Shandong Luoxin”), won the bid for cefathiamidine for injection and cefazoxime sodium for injection. The relevant information is hereby announced as follows:
1、 Basic information of bid winning products
Drug name registration is divided into indication specification, packaging specification, procurement area, procurement category cycle
The original chemical for injection is used for the respiratory system caused by sensitive bacteria, 0.5g per bottle
Cephalosporin 6 series, hepatobiliary system, facial features and urinary tract sensation
Amidine staining, endocarditis and sepsis. 1g, 1 bottle / piece
Lower respiratory tract infection caused by sensitive bacteria, 1 bottle / branch, 1 year urinary tract infection, abdominal infection and pelvic infection in Jiangxi Province, 0.5g
Original chemical stain for injection, sepsis, skin and soft tissue infection
Cefazole drugs 6 bone and joint infections, Streptococcus pneumoniae or
Meningitis caused by Haemophilus influenzae with sodium oxime and 1.0g, 1 bottle / piece
Simple gonorrhea.
Note: the actual purchase quantity of the above varieties shall be subject to the final signed purchase contract.
2、 Impact of this bid on the company
The company’s annual sales of cefathiamidine for injection in 2021 was 147403 million yuan, accounting for 0.23% of the main business income in 2021; The sales of cefazoxime sodium for injection in 2021 was 1088508 million yuan, accounting for 1.71% of the main business income in 2021.
In terms of the implementation of this centralized procurement with quantity, the medical institutions in the alliance area are required to give priority to the selected drugs in this centralized procurement of drugs in the procurement cycle, and ensure the completion of the agreed procurement quantity. The subsequent signing and implementation of the purchase contract by the company will help to expand the sales of the selected products in the alliance areas of Jiangxi, Guangdong, Henan and Hubei provinces, improve the market share of the selected products, enhance the brand influence of the company, and have a positive impact on the future business performance of the company. 3、 Other instructions
Namefen hydrochloride injection and cefotaxime sodium for injection, which the company participated in the bidding, failed to win the bid. Due to the small sales volume of the above products, it will not have a significant impact on the production and operation of the company. The company will actively promote the sales and promotion of the above products in other channels to reduce the impact of bid failure.
4、 Risk tips
At present, the bid winning information of cefathiamidine for injection and cefazoxime sodium for injection has been announced. The signing of the purchase contract and the market sales implementation of the above products after volume purchase are still uncertain. Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) board of directors April 5, 2022
